The Asia Pacific Thrombosis And Hemostasis Biomarkers Market would witness market growth of 6.5% CAGR during the forecast period (2023-2030).
Venous thrombosis may be brought on by illness or injury to the leg veins, inability to move around (immobility), a fractured bone, certain medications, obesity, inherited disorders, or a higher likelihood of developing a particular disorder based on genes, autoimmune diseases that increase the risk of blood clotting, and medications that increase the risk of clotting (such as some birth control medications).
The rise in obesity is responsible for rising thrombotic disease morbidity and mortality, including myocardial infarction, stroke, as well as venous thromboembolism. Uncertainty regarding the risks, advantages, and anticoagulant drug dosage in this patient population prevents successful treatment and prevention of thrombosis in obese individuals due to a poor understanding of the core prothrombotic pathways.
IBEF predicts that the Indian pharmaceutical industry will reach $65 billion by 2024 and $130 billion by 2030. The pharmaceutical industry in India is currently worth $50 billion. India is a prominent international supplier of pharmaceuticals, with its exports to more than 200 countries. In the financial year 2021-2022, the pharmaceutical industry, along with the chemical and botanical product industries, had a mean industrial production index of 221.6. The export of pharmaceutical and medical items was $24.6 billion in 2021–2022. Additionally, according to the latest figures from the National Health Accounts (NHA) 2022 report from Niti Aayog published in April 2023, India's government health expenditure (GHE) accounted for 1.35% of the total GDP in 2019-20.
The China market dominated the Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $580.2 million by 2030. The Japan market is estimated to grow a CAGR of 5.9% during (2023 - 2030). Additionally, The India market would exhibit a CAGR of 7.2% during (2023 - 2030).
Based on Product, the market is segmented into Reagents & Consumables, and Analyzers. Based on Application, the market is segmented into Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Disseminated Intravascular Coagulation (DIC) & Others. Based on End-use, the market is segmented into Diagnostic Centers, Hospitals & Clinics, and Academic & Research Institutes and Others. Based on Location, the market is segmented into Clinical Laboratory Tests, and Point-of-Care Tests. Based on Type, the market is segmented into Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, D-Dimer, Anti-Thrombin III, Plasminogen & Fibrinogen, Soluble Fibrin, Selectins, Factor VIII, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Thrombosis And Hemostasis Biomarkers Market is Projected to reach USD 7.4 Billion by 2030, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMérieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).
By Product
By Application
By End-Use
By Location
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
